Trials / Completed
CompletedNCT02565758
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
- Undifferentiated Pleomorphic Sarcoma
- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma of the Breast
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-085 | Administered as an intravenous infusion in 28-day dosing cycles. |
Timeline
- Start date
- 2015-09-18
- Primary completion
- 2019-03-25
- Completion
- 2019-03-25
- First posted
- 2015-10-01
- Last updated
- 2019-04-05
Locations
20 sites across 3 countries: United States, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02565758. Inclusion in this directory is not an endorsement.